|
JUNE 24th, 2005
OrthoLogic Strives to Turn Bone Repair into an Exact Science
OrthoLogic Corp. (NASDAQ:OLGC) announced the publication of a preclinical study related
to its Chrysalin (TP508) fracture repair program. The journal of Orthopaedic Research, affiliated with the Orthopedic Research
Society, published details about the study.
One of the study's goal was to determine if Chrysalin, when injected
into an experimental fracture, would upregulate genes that control the inflammatory phase of fracture repair and result in
new vasculature into the fracture callus. Affymetrix's genomescale profiling was used in the study.
The study indicated that Chrysalin "induced expression of inflammatory
response modifiers and angiogenesis-related genes." As well, the study showed that Chrysalin accelerated fracture repair.
Mechanical tests were used to test bone strength.
JUNE 7th, 2005
Millenium Biologix Corporation (TSX: MBC), a company with research
operations in skeletal tissue regeneration products, has reported a 25 percent increase in revenue for the fifteen month period
ended March 31, 2005 when compared to the 12 month period ended December 31, 2005. For the 15 months ended March 31, 2005,
sales of Millenium's Skelite products, its skeletal regeneration product, were reported to be $1.54 million compared to $0.9
million for the twelve months ended December 31, 2005. Total sales for the same two periods were $2.5 million and $2.0 million
respectively.
The company pointed to initial strength in sales of its Skelite
implantable synthetic bone graft products, but indicated that overstocking by its distributor in 2004, resulted in minimal
shipments in the last 9 months of its fiscal 2005 year. The company did not elaborate as to why it used unequal time periods
for comparison purposes.
Millenium, a regenerative medicine company, bases its products on
advanced biomaterials, biologics and engineering. With this as the basis, the company has designed its product to facilitate
the repair and natural healing of human bone and associated connecting tissues like cartilage.
APRIL 25th, 2005
American HealthChoice, Inc. (OTC:AMHI) announced that it obtained
a $500,000 line of credit from Northern Healthcare Capital, LLC. The funds are planned for the marketing of the DRX9000 Spinal
Decompression System, a non-surgical method, which relieves lower back pain and pressure between the discs of the spine. The
product is marketed through RehabCo, a subsidiary of the company.
|
